Global Health Limited (MEDANTA) fair value: what the stock is really worth
As of Oct 5, 2026: fair value of Global Health Limited ₹438, price ₹1,333, upside -67.1%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
47‑month range ₹413.85 – ₹1,509 · fair‑value band ₹328.27 – ₹548.60 · the ₹1,333 price screens above the ₹438.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.
Follow Global Health in your weekly email
Every Wednesday you see whether Global Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Global Health Limited, together with its subsidiaries, provides healthcare services in India.
Show more
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
Stock analysis
Global Health Limited (MEDANTA) currently trades at ₹1,333, while our model-based Fair Value estimate is ₹438.43, 67.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹573.41 per share, and 0 of the 16 models we run sit above the ₹1,333 price.
Bear case: the Asset-Based group reads lowest at ₹98.77, and 16 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹328.27 (bear) to ₹548.60 (bull), the price of ₹1,333 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Global Health Limited reported revenue of ₹44.1B in FY2026 versus ₹21.7B in FY2022, a compound +19.4%/yr. Reported net income was ₹5.6B in FY2026, compounding +29.8%/yr from FY2022.
Key figures
Market cap ₹402B (≈ $4.2B) · P/E ratio 64.6 · P/S ratio 8.15 · EPS (TTM) ₹20.64 · Dividend yield 0.0% · Net margin 12.6% · Return on equity 15.0% · Return on assets (EBIT) 13.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −67%, MEDANTA screens richer than that median.
Fair Value models
Bear ₹328.27Fair Value ₹438.43Bull ₹548.60
Price ₹1,333 · Upside -67.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹10.43 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+21.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.3%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+70.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+70.3%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 16%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 251 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−67.1% · Bottom 25%
Profitability
Return on equity (TTM)15.0% · Above median
Return on assets8.2% · Top 25%
Net margin (TTM)11.9% · Top 25%
Operating margin (TTM)16.7% · Top 25%
Growth and dividend
Revenue growth26.5% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.15× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)64.6× · Priciest 25%
P/B10.14× · Priciest 25%
P/S (TTM)8.58× · Priciest 25%
EV/EBITDA41.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)100· sector 26
PAST (return on equity)60· sector 32
HEALTH (low debt)92· sector 90
DIVIDEND (yield)1· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Global Health Limited Fair Value". https://www.fairvalue-calculator.com/stock/MEDANTA
Frequently asked questions
Is Global Health Limited (MEDANTA) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of ₹438.43 versus a price of ₹1,333, about −67% upside (overvalued).
What is the fair value of MEDANTA?
Our model-based fair value for Global Health Limited is ₹438.43 (as of Sep 28, 2026), built from audited fundamentals. The current price: ₹1,333.
What is the quality score of MEDANTA?
Global Health Limited has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Global Health Limited (MEDANTA)?
Our model-based price target is the fair value of ₹438.43 (as of Sep 28, 2026) from 16 valuation models. Cautious scenario ₹328.27, optimistic scenario ₹548.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Global Health Limited stock forecast for 2026?
Our models put fair value at ₹438.43, about −67% upside versus a price of ₹1,333 (overvalued). Cautious scenario ₹328.27, optimistic scenario ₹548.60. The calculation is refreshed regularly with new filings.
What is the revenue of Global Health Limited (MEDANTA)?
Global Health Limited reported trailing-twelve-month revenue of about ₹46.8B (latest available figure, as of Sep 28, 2026).
Does Global Health Limited pay a dividend?
Global Health Limited currently shows a dividend yield of about 0.04% relative to its recent price (as of Sep 28, 2026).
What is the intrinsic value of Global Health Limited (MEDANTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Global Health Limited it is ₹438.43 per share (as of Sep 28, 2026), against a price of ₹1,333. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Global Health Limited stock overvalued or undervalued in 2026?
As of Sep 28, 2026, MEDANTA trades above its calculated fair value: price ₹1,333, fair value ₹438.43, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDANTA?
No. The price is what the market pays today (₹1,333); the fair value is what the company's own numbers justify (₹438.43). For Global Health Limited the two are ₹894.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Global Health Limited worth?
The market values Global Health Limited at about ₹402B (market capitalisation, as of Sep 28, 2026). Per share that is ₹1,333; our models calculate a fair value of ₹438.43 per share.
What do the bullish and bearish scenarios say about MEDANTA?
Our models span a range for Global Health Limited: cautious scenario ₹328.27, base ₹438.43, optimistic ₹548.60 per share (as of Sep 28, 2026, price ₹1,333). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDANTA?
Global Health Limited trades at a price-to-earnings ratio of 64.6 (as of Sep 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹438.43 is built from several models across several years. Other multiples: P/B 10.1, P/S 8.6, EV/EBITDA 41.0.
How solid is the balance sheet of Global Health Limited (MEDANTA)?
Balance-sheet figures for Global Health Limited (as of Sep 28, 2026): return on equity 15.0%, debt of 0.15 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is MEDANTA from its 52-week high?
Global Health Limited trades at ₹1,333, about 12% below its 52-week high of ₹1,509 and 39% above the low of ₹960.76 (as of Oct 5, 2026). Distance from the high says nothing about value: that is what the fair value of ₹438.43 is for.
Which stocks are comparable to Global Health Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Global Health Limited stock attractive at the current price?
The data as of Sep 28, 2026: price ₹1,333, calculated fair value ₹438.43 (−67%), Quality Score 51/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDANTA calculated?
We run Global Health Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹438.43, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Global Health Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Global Health Limited (MEDANTA)?
The closing price on Oct 5, 2026 was ₹1,333. Our model-based fair value is ₹438.43, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Global Health Limited right now?
The price sits above even our optimistic bull case (₹548.60). The favourable scenario is already priced in. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Global Health Limited
How large is the market capitalisation of Global Health Limited (MEDANTA)?
The market capitalisation of Global Health Limited is ₹402B (≈ $4.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Global Health Limited (MEDANTA)?
The price-to-sales ratio of Global Health Limited is 8.15 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Global Health Limited (MEDANTA)?
Earnings per share at Global Health Limited are ₹20.64 (price ÷ EPS = P/E 64.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Global Health Limited (MEDANTA)?
The dividend yield of Global Health Limited is 0.0% (payout 2.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Global Health Limited (MEDANTA)?
The net margin of Global Health Limited is 12.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Global Health Limited (MEDANTA)?
The return on equity (ROE) of Global Health Limited is 15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Global Health Limited (MEDANTA)?
On an EBIT basis the return on assets of Global Health Limited is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Global Health Limited (MEDANTA)?
The operating margin of Global Health Limited is 16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Global Health Limited (MEDANTA)?
Revenue at Global Health Limited is growing +26.5% versus a year earlier (3y avg +18.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Global Health Limited (MEDANTA)?
Earnings per share at Global Health Limited are growing −0.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Global Health Limited (MEDANTA) generate?
The free cash flow of Global Health Limited is −₹2.3B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Global Health Limited (MEDANTA) carry?
The net debt of Global Health Limited is ₹598M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Global Health Limited in the live analysis
One click puts Global Health Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
